Abeona Therapeutics Inc. - Common Stock (ABEO)

Intrigued by the market activity one hour before the close of the markets on Wednesday? Uncover the key winners and losers of today's session in our insightful analysis.

Abeona's Zevaskyn secures timely FDA nod, priced at $3.1 million, with 2025 sales now forecast at $31.6 million and peak U.S. revenue projected at $600 million.

Abeona shares are trading higher on Wednesday on possible continued strength after the FDA announced approval for its gene therapy.

Looking for insights into the US markets in the middle of the day on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

FDA approves Zevaskyn as the first cell-based gene therapy for RDEB wounds after strong results in pivotal and long-term studies.

ZEVASKYN is expected to be available beginning in the third quarter of 2025 through ZEVASKYN Qualified Treatment Centers, located across the U.S. with experience in cell and gene therapy.

ABEO stock results show that Abeona Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.

ABEO stock results show that Abeona Therapeutics missed analyst estimates for earnings per share the first quarter of 2024.

Affirm stock is falling on Tuesday as AFRM investors react to BNPL loan service One being added to Walmart's retail stores.

Abeona Therapeutics' pz-cel gets the FDA's Complete Response Letter and Abeona's plans for fulfilling Chemistry Manufacturing and Controls requirements.

Greenwave Technology Solutions stock is down on Tuesday as GWAV investors react to a registered direct offering and private placement.

Abeona Therapeutics stock is falling on Tuesday after the FDA sent it a CRL for more CMC data before it would approve Pz-cel.

We're diving into the biggest pre-market stock movers that traders are going to want to keep an eye on for Tuesday morning!